



CATARACTS MEASURES GROUP

Similar to the Diabetic Retinopathy Measures Group, these measures must be reported by a qualified registry, such as the American Academy of Ophthalmology [IRIS® Registry](#). The 8 measures below must be reported on 20 patients, 11 of which must have traditional Medicare Part B insurance.

The last day to register with IRIS Registry is August 1, 2016 for those new to IRIS Registry reporting.

Measure 130	Documentation of Current Medications in the Medical Record
Measure 191	Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
Measure 192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures
Measure 226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
Measure 303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery
Measure 304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery
Measure 388	Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule Requiring Unplanned Vitrectomy)
Measure 389	Cataract Surgery: Difference Between Planned and Final Refraction

Requirements:

- You must report on 20 unique procedures performed on patients aged 18 years and older.
- Of the 20, at least 11 procedures must be performed on patients with Medicare Part B insurance. The remaining patients may have Medicare Advantage or commercial insurance.
- Only procedures performed from January 1 through September 30, 2016 are eligible for reporting.
- One of the following procedure codes indicating cataract surgery: 66840, 66850, 66852, 66920, 66930, 66940, 66983, 66984

Note: CPT code 66982 is excluded from this measures group. Any patient that has complex cataract surgery is unable to be included as of the 20 unique patients.



- Procedures with the use of modifiers -55 (postoperative management only) or 56 (preoperative management only) are excluded from this measures group.
- Measures 191 and 192 do not need to be reported (are not applicable) when the patient also has a diagnosis of complicated cataract. Refer to the measure specification on the following pages for specific codes indicating a diagnosis of complicated cataract for each of these two measures.
- Measure 388 does not need to be reported (is not applicable) when history of preoperative posterior capsule rupture.
- Measures 303 and 304 require the distribution of patient surveys. Measure 303 requires the distribution of both a preoperative and postoperative visual function survey. Measure 304 requires the distribution of a postoperative consumer satisfaction survey. You can only include procedures where the patient was distributed all surveys; the preoperative visual function survey **MUST** be provided prior to surgery.

Measure 130: Documentation of Current Medications in the Medical Record

Quality Domain: Patient Safety

Description: Percentage of visits for patients aged 18 years and older for which the eligible professional attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include all known prescriptions, over-the-counters, herbals, and vitamin/mineral/dietary (nutritional) supplements and must contain the medications' name, dosage, frequency and route of administration.

Numerator: Eligible professional attests to documenting, updating or reviewing a patient's current medications using all immediate resources available on the date of encounter. This list must include ALL known prescriptions, over-the counters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications' name, dosages, frequency and route of administration.

The eligible professional must document in the medical record they obtained, updated, or reviewed a medication list on the date of the encounter. Eligible professionals reporting this measure may document medication information received from the patient, authorized representative(s), caregiver(s) or other available healthcare resources

Definitions:

Current Medications – Medications the patient is presently taking including all prescriptions, over-the-counters, herbals and vitamin/mineral/dietary (nutritional) supplements with each medication's name, dosage, frequency and administered route.



Route - Documentation of the way the medication enters the body (some examples include but are not limited to: oral, sublingual, subcutaneous injections, and/or topical).

Not Eligible - A patient is not eligible if the following reason is documented:

- Patient is in an urgent or emergent medical situation where time is of the essence and to delay treatment would jeopardize the patient's health status.

Numerator Options:

G8427 List of current medications with name, dosages, frequency and route documented;

Or

G8430 Provider documentation that patient is not eligible for medication assessment;

Or

G8428 Current medications with name, dosages, frequency, route not documented, reason not specified

Measure 191 Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery

Quality Domain: Effective Clinical Care

Description: Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and no significant ocular conditions impacting the visual outcome of surgery and had best-corrected visual acuity of 20/40 or better (distance or near) achieved within 90 days following the cataract surgery

Note:

- For patients who receive the cataract surgical procedures specified in the common denominator coding, it should be reported whether or not the patient had best-corrected visual acuity of 20/40 or better achieved within 90 days following cataract surgery.
- Patients who have any of the listed significant ocular conditions [comorbid] in the exclusion criteria should be removed from the denominator; these patients have existing ocular conditions that could impact the outcome of surgery and are not included in the measure calculation for those patients who have best-corrected visual acuity of 20/40 or better (distance or near) achieved within 90 days following the cataract surgery.



- Patients with documentation of the presence of one or more of the listed significant ocular conditions that impact the visual outcome of surgery prior to date of cataract surgery which is still active at the time of the cataract surgery are excluded from the measure calculation:

Acute and Subacute Iridocyclitis

H20.00, H20.011, H20.012, H20.013, H20.019, H20.021, H20.022, H20.023, H20.029, H20.031, H20.032, H20.033, H20.039, H20.041, H20.042, H20.043, H20.049, H20.051, H20.052, H20.053, H20.059

Amblyopia

H53.011, H53.012, H53.013, H53.019, H53.021, H53.022, H53.023, H53.029, H53.031, H53.032, H53.033, H53.039

Burn Confined to Eye and Adnexa

T26.00XA, T26.01XA, T26.02XA, T26.10XA, T26.11XA, T26.12XA, T26.20XA, T26.21XA, T26.22XA, T26.30XA, T26.31XA, T26.32XA, T26.40XA, T26.41XA, T26.42XA, T26.50XA, T26.51XA, T26.52XA, T26.60XA, T26.61XA, T26.62XA, T26.70XA, T26.71XA, T26.72XA, T26.80XA, T26.81XA, T26.82XA, T26.90XA, T26.91XA, T26.92XA

Cataract Secondary to Ocular Disorders

H26.211, H26.212, H26.213, H26.219, H26.221, H26.222, H26.223, H26.229

Central Corneal Ulcer

H16.011, H16.012, H16.013, H16.019

Certain Types of Iridocyclitis

H20.20, H20.21, H20.22, H20.23, H20.811, H20.812, H20.813, H20.819, H20.821, H20.822, H20.823, H20.829, H20.9, H40.40X0

Choroidal Degenerations

H35.33

Choroidal Detachment

H31.411, H31.412, H31.413, H31.419

Choroidal Hemorrhage and Rupture

H31.301, H31.302, H31.303, H31.309, H31.311, H31.312, H31.313, H31.319, H31.321, H31.322, H31.323, H31.329

Chorioretinal Scars

H31.001, H31.002, H31.003, H31.009, H31.011, H31.012, H31.013, H31.019, H31.021, H31.022, H31.023, H31.029, H31.091, H31.092, H31.093, H31.099



Chronic Iridocyclitis

A18.54, H20.10, H20.11, H20.12, H20.13, H20.9

Cloudy Cornea

H17.00, H17.01, H17.02, H17.03, H17.10, H17.11, H17.12, H17.13, H17.811, H17.812, H17.813, H17.819, H17.821, H17.822, H17.823, H17.829

Corneal Opacity and Other Disorders of Cornea

H17.00, H17.01, H17.02, H17.03, H17.10, H17.11, H17.12, H17.13, H17.89, H17.9

Corneal Edema

H18.10, H18.11, H18.12, H18.13, H18.20, H18.221, H18.222, H18.223, H18.229, H18.231, H18.232, H18.233, H18.239, H18.421, H18.422, H18.423, H18.429, H18.43

Degeneration of Macula and Posterior Pole

H35.30, H35.31, H35.32, H35.341, H35.342, H35.343, H35.349, H35.351, H35.352, H35.353, H35.359, H35.361, H35.362, H35.363, H35.369, H35.371, H35.372, H35.373, H35.379, H35.381, H35.382, H35.383, H35.389

Degenerative Disorders of Globe

H44.20, H44.21, H44.22, H44.23, H44.311, H44.312, H44.313, H44.319, H44.321, H44.322, H44.323, H44.329, H44.391, H44.392, H44.393, H44.399

Diabetic Macular Edema

E08.311, E08.321, E08.331, E08.341, E08.351, E09.311, E09.321, E09.331, E09.341, E09.351, E10.311, E10.321, E10.331, E10.341, E10.351, E11.311, E11.321, E11.331, E11.341, E11.351, E13.311, E13.321, E13.331, E13.341, E13.351

Diabetic Retinopathy

E08.311, E08.319, E08.321, E08.329, E08.331, E08.339, E08.341, E08.349, E08.351, E08.359, E09.311, E09.319, E09.321, E09.329, E09.331, E09.339, E09.341, E09.349, E09.351, E09.359, E10.311, E10.319, E10.321, E10.329, E10.331, E10.339, E10.341, E10.349, E10.351, E10.359, E11.311, E11.319, E11.321, E11.329, E11.331, E11.339, E11.341, E11.349, E11.351, E11.359, E13.311, E13.319, E13.321, E13.329, E13.331, E13.339, E13.341, E13.349, E13.351, E13.359

Disorders of Optic Chiasm

H47.41, H47.42, H47.43, H47.49

Disorders of Visual Cortex

H47.611, H47.612, H47.619



Disseminated Chorioretinitis and Disseminated Retinochoroiditis

A18.53, H30.101, H30.102, H30.103, H30.109, H30.111, H30.112, H30.113, H30.119, H30.121, H30.122, H30.123, H30.129, H30.131, H30.132, H30.133, H30.139, H30.141, H30.142, H30.143, H30.149

Focal Chorioretinitis and Focal Retinochoroiditis

H30.001, H30.002, H30.003, H30.009, H30.011, H30.012, H30.013, H30.019, H30.021, H30.022, H30.023, H30.029, H30.031, H30.032, H30.033, H30.039, H30.041, H30.042, H30.043, H30.049

Glaucoma

H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.11X0, H40.11X1, H40.11X2, H40.11X3, H40.11X4, H40.1210, H40.1211, H40.1212, H40.1213, H40.1214, H40.1220, H40.1221, H40.1222, H40.1223, H40.1224, H40.1230, H40.1231, H40.1232, H40.1233, H40.1234, H40.1290, H40.1291, H40.1292, H40.1293, H40.1294, H40.1310, H40.1311, H40.1312, H40.1313, H40.1314, H40.1320, H40.1321, H40.1322, H40.1323, H40.1324, H40.1330, H40.1331, H40.1332, H40.1333, H40.1334, H40.1390, H40.1391, H40.1392, H40.1393, H40.1394, H40.1410, H40.1411, H40.1412, H40.1413, H40.1414, H40.1420, H40.1421, H40.1422, H40.1423, H40.1424, H40.1430, H40.1431, H40.1432, H40.1433, H40.1434, H40.1490, H40.1491, H40.1492, H40.1493, H40.1494, H40.151, H40.152, H40.153, H40.159, H40.20X0, H40.20X1, H40.20X2, H40.20X3, H40.20X4, H40.211, H40.212, H40.213, H40.219, H40.2210, H40.2211, H40.2212, H40.2213, H40.2214, H40.2220, H40.2221, H40.2222, H40.2223, H40.2224, H40.2230, H40.2231, H40.2232, H40.2233, H40.2234, H40.2290, H40.2291, H40.2292, H40.2293, H40.2294, H40.231, H40.232, H40.233, H40.239, H40.241, H40.242, H40.243, H40.249, H40.30X0, H40.30X1, H40.30X2, H40.30X3, H40.30X4, H40.31X0, H40.31X1, H40.31X2, H40.31X3, H40.31X4, H40.32X0, H40.32X1, H40.32X2, H40.32X3, H40.32X4, H40.33X0, H40.33X1, H40.33X2, H40.33X3, H40.33X4, H40.40X0, H40.40X1, H40.40X2, H40.40X3, H40.40X4, H40.41X0, H40.41X1, H40.41X2, H40.41X3, H40.41X4, H40.42X0, H40.42X1, H40.42X2, H40.42X3, H40.42X4, H40.43X0, H40.43X1, H40.43X2, H40.43X3, H40.43X4, H40.50X0, H40.50X1, H40.50X2, H40.50X3, H40.50X4, H40.51X0, H40.51X1, H40.51X2, H40.51X3, H40.51X4, H40.52X0, H40.52X1, H40.52X2, H40.52X3, H40.52X4, H40.53X0, H40.53X1, H40.53X2, H40.53X3, H40.53X4, H40.60X0, H40.60X1, H40.60X2, H40.60X3, H40.60X4, H40.61X0, H40.61X1, H40.61X2, H40.61X3, H40.61X4, H40.62X0, H40.62X1, H40.62X2, H40.62X3, H40.62X4, H40.63X0, H40.63X1, H40.63X2, H40.63X3, H40.63X4, H40.811, H40.812, H40.813, H40.819, H40.821, H40.822, H40.823, H40.829, H40.831, H40.832, H40.833, H40.839, H40.89, Q15.0

Glaucoma Associated with Congenital Anomalies, Dystrophies, and Systemic Syndromes

H40.30X0, H40.30X1, H40.30X2, H40.30X3, H40.30X4, H40.31X0, H40.31X1, H40.31X2, H40.31X3, H40.31X4, H40.32X0, H40.32X1, H40.32X2, H40.32X3, H40.32X4, H40.33X0, H40.33X1, H40.33X2, H40.33X3, H40.33X4, H40.40X0, H40.40X1, H40.40X2, H40.40X3, H40.40X4, H40.41X0, H40.41X1, H40.41X2, H40.41X3, H40.41X4, H40.42X0, H40.42X1, H40.42X2, H40.42X3, H40.42X4, H40.43X0, H40.43X1, H40.43X2, H40.43X3, H40.43X4, H40.50X0, H40.50X1, H40.50X2, H40.50X3, H40.50X4, H40.51X0, H40.51X1, H40.51X2, H40.51X3, H40.51X4, H40.52X0, H40.52X1, H40.52X2, H40.52X3, H40.52X4, H40.53X0, H40.53X1, H40.53X2, H40.53X3, H40.53X4, H40.811, H40.812, H40.813, H40.819, H40.821, H40.822, H40.823, H40.829, H40.831, H40.832, H40.833, H40.839, H40.89, H40.9, H42



Hereditary Choroidal Dystrophies

H31.20, H31.21, H31.22, H31.23, H31.29

Hereditary Corneal Dystrophies

H18.50, H18.51, H18.52, H18.53, H18.54, H18.55, H18.59

Hereditary Retinal Dystrophies

H35.50, H35.51, H35.52, H35.53, H35.54, H36

Injury to Optic Nerve and Pathways

S04.011A, S04.012A, S04.019A, S04.02XA, S04.031A, S04.032A, S04.039A, S04.041A, S04.042A, S04.049A

Moderate or Severe Impairment, Better Eye, Profound Impairment Lesser Eye

H54.10, H54.11, H54.12

Nystagmus and Other Irregular Eye Movements

H55.01

Open Wound of Eyeball

S05.10XA, S05.11XA, S05.12XA, S05.20XA, S05.21XA, S05.22XA, S05.30XA, S05.31XA, S05.32XA, S05.50XA, S05.51XA, S05.52XA, S05.60XA, S05.61XA, S05.62XA, S05.70XA, S05.71XA, S05.72XA, S05.8X1A, S05.8X2A, S05.8X9A, S05.90XA, S05.91XA, S05.92XA

Optic Atrophy

H47.20, H47.211, H47.212, H47.213, H47.219, H47.22, H47.231, H47.232, H47.233, H47.239, H47.291, H47.292, H47.293, H47.299

Optic Neuritis

H46.00, H46.01, H46.02, H46.03, H46.10, H46.11, H46.12, H46.13, H46.2, H46.3, H46.8, H46.9

Other Background Retinopathy and Retinal Vascular Changes

H35.021, H35.022, H35.023, H35.029, H35.051, H35.052, H35.053, H35.059, H35.061, H35.062, H35.063, H35.069

Other Corneal Deformities

H18.70, H18.711, H18.712, H18.713, H18.719, H18.721, H18.722, H18.723, H18.729, H18.731, H18.732, H18.733, H18.739, H18.791, H18.792, H18.793, H18.799

Other Disorders of Optic Nerve



H47.011, H47.012, H47.013, H47.019

Other Disorders of Sclera

H15.831, H15.832, H15.833, H15.839, H15.841, H15.842, H15.843, H15.849

Other Endophthalmitis

H16.241, H16.242, H16.243, H16.249, H21.331, H21.332, H21.333, H21.339, H33.121, H33.122, H33.123, H33.129, H44.111, H44.112, H44.113, H44.119, H44.121, H44.122, H44.123, H44.129, H44.131, H44.132, H44.133, H44.139, H44.19

Other Proliferative Retinopathy

H35.101, H35.102, H35.103, H35.109, H35.111, H35.112, H35.113, H35.119, H35.121, H35.122, H35.123, H35.129, H35.131, H35.132, H35.133, H35.139, H35.141, H35.142, H35.143, H35.149, H35.151, H35.152, H35.153, H35.159, H35.161, H35.162, H35.163, H35.169, H35.171, H35.172, H35.173, H35.179

Other Retinal Disorders

H35.60, H35.61, H35.62, H35.63, H35.81, H35.82, H35.89

Other and Unspecified Forms of Chorioretinitis and Retinochoroiditis

H30.20, H30.21, H30.22, H30.23, H30.811, H30.812, H30.813, H30.819, H30.891, H30.892, H30.893, H30.899, H30.90, H30.91, H30.92, H30.93

Pathologic Myopia

H44.20, H44.21, H44.22, H44.23, H44.30

Prior Penetrating Keratoplasty

H18.601, H18.602, H18.603, H18.609, H18.611, H18.612, H18.613, H18.619, H18.621, H18.622, H18.623, H18.629

Profound Impairment, Both Eyes

H54.0, H54.10

Purulent Endophthalmitis

H44.001, H44.002, H44.003, H44.009, H44.011, H44.012, H44.013, H44.019, H44.021, H44.022, H44.023, H44.029

Retinal Detachment with Retinal Defect

H33.001, H33.002, H33.003, H33.009, H33.011, H33.012, H33.013, H33.019, H33.021, H33.022, H33.023, H33.029, H33.031, H33.032, H33.033, H33.039, H33.041, H33.042, H33.043, H33.049, H33.051, H33.052, H33.053, H33.059, H33.8



Retinal Vascular Occlusion

H34.10, H34.11, H34.12, H34.13, H34.231, H34.232, H34.233, H34.239, H34.811, H34.812, H34.813, H34.819, H34.831, H34.832, H34.833, H34.839

Scleritis and Episcleritis

A18.51, H15.021, H15.022, H15.023, H15.029, H15.031, H15.032, H15.033, H15.039, H15.041, H15.042, H15.043, H15.049, H15.051, H15.052, H15.053, H15.059, H15.091, H15.092, H15.093, H15.099

Separation of Retinal Layers

H35.711, H35.712, H35.713, H35.719, H35.721, H35.722, H35.723, H35.729, H35.731, H35.732, H35.733, H35.739

Uveitis

H44.111, H44.112, H44.113, H44.119, H44.131, H44.132, H44.133, H44.139

Visual Field Defects

H53.411, H53.412, H53.413, H53.419

Numerator Options:

4175F Best-corrected visual acuity of 20/40 or better (distance or near) achieved within 90 days following cataract surgery

or

4175F 8P Best corrected visual acuity of 20/40 or better (distance or near) not achieved within 90 days following cataract surgery, reason not otherwise specified.

Measure 192: Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures

Quality Domain: Patient Safety

Description: Percentage of patients aged 18 years and older with a diagnosis of uncomplicated cataract who had cataract surgery and had any of a specified list of surgical procedures in the 30 days following cataract surgery which would indicate the occurrence of any of the following major complications: retained nuclear fragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, or wound dehiscence.



Note:

- For patients who receive the cataract surgical procedures specified in the denominator coding, claims should be reviewed to determine if any of the procedure codes listed in the numerator were performed within 30 days of the date of cataract surgery.
- Patients who have any of the listed significant ocular conditions in the exclusion criteria should be removed from the denominator, and not considered as having a complication within 30 days following cataract surgery.
- Patients with documentation of the presence of one or more of the listed significant ocular conditions that impact the surgical complication rate prior to date of cataract surgery which is still active at the time of the cataract surgery are excluded from the measure calculation.

Prior Pars Plana Vitrectomy

67036, 67039, 67040, 67041, 67042, 67043 (patient with history of this procedure)

Acute and Subacute Iridocyclitis

H20.00, H20.011, H20.012, H20.013, H20.019, H20.021, H20.022, H20.023, H20.029, H20.031, H20.032, H20.033, H20.039, H20.041, H20.042, H20.043, H20.049, H20.051, H20.052, H20.053, H20.059

Adhesions and Disruptions of Iris and Ciliary Body

H21.40, H21.41, H21.42, H21.43, H21.501, H21.502, H21.503, H21.509, H21.511, H21.512, H21.513, H21.519, H21.521, H21.522, H21.523, H21.529, H21.531, H21.532, H21.533, H21.539, H21.541, H21.542, H21.543, H21.549, H21.551, H21.552, H21.553, H21.559, H21.561, H21.562, H21.563, H21.569, H21.81, H21.82, H21.89, H22

Anomalies of Pupillary Function

H57.03

Aphakia and Other Disorders of Lens

H27.10, H27.111, H27.112, H27.113, H27.119, H27.121, H27.122, H27.123, H27.129, H27.131, H27.132, H27.133, H27.139

Burn Confined to Eye and Adnexa

T26.00XA, T26.01XA, T26.02XA, T26.10XA, T26.11XA, T26.12XA, T26.20XA, T26.21XA, T26.22XA, T26.30XA, T26.31XA, T26.32XA, T26.40XA, T26.41XA, T26.42XA, T26.50XA, T26.51XA, T26.52XA, T26.60XA, T26.61XA, T26.62XA, T26.70XA, T26.71XA, T26.72XA, T26.80XA, T26.81XA, T26.82XA, T26.90XA, T26.91XA, T26.92XA

Cataract Secondary to Ocular Disorders

H26.211, H26.212, H26.213, H26.219, H26.221, H26.222, H26.223, H26.229



Cataract, Congenital

Q12.0

Cataract, Mature or Hypermature

H26.9

Cataract, Posterior Polar

Q12.0

Central Corneal Ulcer

H16.011, H16.012, H16.013, H16.019

Certain Types of Iridocyclitis

H20.20, H20.21, H20.22, H20.23, H20.811, H20.812, H20.813, H20.819, H20.821, H20.822, H20.823, H20.829, H20.9, H40.40X0

Chronic Iridocyclitis

A18.54, H20.10, H20.11, H20.12, H20.13, H20.9

Cloudy Cornea

H17.00, H17.01, H17.02, H17.03, H17.10, H17.11, H17.12, H17.13, H17.811, H17.812, H17.813, H17.819, H17.821, H17.822, H17.823, H17.829

Corneal Opacity and Other Disorders of Cornea

H17.00, H17.01, H17.02, H17.03, H17.10, H17.11, H17.12, H17.13, H17.89, H17.9

Corneal Edema

H18.10, H18.11, H18.12, H18.13, H18.20, H18.221, H18.222, H18.223, H18.229, H18.231, H18.232, H18.233, H18.239, H18.421, H18.422, H18.423, H18.429, H18.43

Cysts of Iris, Ciliary Body, and Anterior Chamber

H21.301, H21.302, H21.303, H21.309, H21.311, H21.312, H21.313, H21.319, H21.321, H21.322, H21.323, H21.329, H21.341, H21.342, H21.343, H21.349, H21.351, H21.352, H21.353, H21.359

Enophthalmos

H05.401, H05.402, H05.403, H05.409, H05.411, H05.412, H05.413, H05.419, H05.421, H05.422, H05.423, H05.429

Glaucoma



H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.11X0, H40.11X1, H40.11X2, H40.11X3, H40.11X4, H40.1210, H40.1211, H40.1212, H40.1213, H40.1214, H40.1220, H40.1221, H40.1222, H40.1223, H40.1224, H40.1230, H40.1231, H40.1232, H40.1233, H40.1234, H40.1290, H40.1291, H40.1292, H40.1293, H40.1294, H40.1310, H40.1311, H40.1312, H40.1313, H40.1314, H40.1320, H40.1321, H40.1322, H40.1323, H40.1324, H40.1330, H40.1331, H40.1332, H40.1333, H40.1334, H40.1390, H40.1391, H40.1392, H40.1393, H40.1394, H40.1410, H40.1411, H40.1412, H40.1413, H40.1414, H40.1420, H40.1421, H40.1422, H40.1423, H40.1424, H40.1430, H40.1431, H40.1432, H40.1433, H40.1434, H40.1490, H40.1491, H40.1492, H40.1493, H40.1494, H40.151, H40.152, H40.153, H40.159, H40.20X0, H40.20X1, H40.20X2, H40.20X3, H40.20X4, H40.211, H40.212, H40.213, H40.219, H40.2210, H40.2211, H40.2212, H40.2213, H40.2214, H40.2220, H40.2221, H40.2222, H40.2223, H40.2224, H40.2230, H40.2231, H40.2232, H40.2233, H40.2234, H40.2290, H40.2291, H40.2292, H40.2293, H40.2294, H40.231, H40.232, H40.233, H40.239, H40.241, H40.242, H40.243, H40.249, H40.30X0, H40.30X1, H40.30X2, H40.30X3, H40.30X4, H40.31X0, H40.31X1, H40.31X2, H40.31X3, H40.31X4, H40.32X0, H40.32X1, H40.32X2, H40.32X3, H40.32X4, H40.33X0, H40.33X1, H40.33X2, H40.33X3, H40.33X4, H40.40X0, H40.40X1, H40.40X2, H40.40X3, H40.40X4, H40.41X0, H40.41X1, H40.41X2, H40.41X3, H40.41X4, H40.42X0, H40.42X1, H40.42X2, H40.42X3, H40.42X4, H40.43X0, H40.43X1, H40.43X2, H40.43X3, H40.43X4, H40.50X0, H40.50X1, H40.50X2, H40.50X3, H40.50X4, H40.51X0, H40.51X1, H40.51X2, H40.51X3, H40.51X4, H40.52X0, H40.52X1, H40.52X2, H40.52X3, H40.52X4, H40.53X0, H40.53X1, H40.53X2, H40.53X3, H40.53X4, H40.60X0, H40.60X1, H40.60X2, H40.60X3, H40.60X4, H40.61X0, H40.61X1, H40.61X2, H40.61X3, H40.61X4, H40.62X0, H40.62X1, H40.62X2, H40.62X3, H40.62X4, H40.63X0, H40.63X1, H40.63X2, H40.63X3, H40.63X4, H40.811, H40.812, H40.813, H40.819, H40.821, H40.822, H40.823, H40.829, H40.831, H40.832, H40.833, H40.839, H40.89, Q15.0

Hereditary Corneal Dystrophies

H18.50, H18.51, H18.52, H18.53, H18.54, H18.55, H18.59

High Hyperopia

H52.00, H52.01, H52.02, H52.03

Hypotony of Eye

H44.40, H44.411, H44.412, H44.413, H44.419, H44.421, H44.422, H44.423, H44.429, H44.431, H44.432, H44.433, H44.439, H44.441, H44.442, H44.443, H44.449

Injury to Optic Nerve and Pathways

S04.011A, S04.012A, S04.019A, S04.02XA, S04.031A, S04.032A, S04.039A, S04.041A, S04.042A, S04.049A

Open Wound of Eyeball

S05.10XA, S05.11XA, S05.12XA, S05.20XA, S05.21XA, S05.22XA, S05.30XA, S05.31XA, S05.32XA, S05.50XA, S05.51XA, S05.52XA, S05.60XA, S05.61XA, S05.62XA, S05.70XA, S05.71XA, S05.72XA, S05.8X1A, S05.8X2A, S05.8X9A, S05.90XA, S05.91XA, S05.92XA



Pathologic Myopia

H44.20, H44.21, H44.22, H44.23, H44.30

Posterior Lenticonus

Q12.2, Q12.4, Q12.8

Pseudoexfoliation Syndrome

H40.1410, H40.1411, H40.1412, H40.1413, H40.1414, H40.1420, H40.1421, H40.1422, H40.1423, H40.1424, H40.1430, H40.1431, H40.1432, H40.1433, H40.1434, H40.1490, H40.1491, H40.1492, H40.1493, H40.1494

Retrolental Fibroplasias

H35.171, H35.172, H35.173, H35.179

Other age-related cataract

H25.89

Traumatic Cataract

H26.101, H26.102, H26.103, H26.109, H26.111, H26.112, H26.113, H26.119, H26.121, H26.122, H26.123, H26.129, H26.131, H26.132, H26.133, H26.139

Use of Systemic Sympathetic Alpha-1a Antagonist Medication for Treatment of Prostatic Hypertrophy
Patient taking tamsulosin hydrochloride: G9503

Uveitis

H44.111, H44.112, H44.113, H44.119, H44.131, H44.132, H44.133, H44.139

Vascular Disorders of Iris and Ciliary Body

H21.1X1, H21.1X2, H21.1X3, H21.1X9

Numerator instructions: Codes for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, or wound dehiscence): 65235, 65860, 65880, 65900, 65920, 65930, 66030, 66250, 66820, 66825, 66830, 66852, 66986, 67005, 67010, 67015, 67025, 67028, 67030, 67031, 67036, 67039, 67041, 67042, 67043, 67101, 67105, 67107, 67108, 67110, 67141, 67145, 67250, 67255

Numerator Options:

G8627 Surgical procedure performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment or wound dehiscence)



or

G8628 Surgical procedure not performed within 30 days following cataract surgery for major complications (e.g., retained nuclear fragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment or wound dehiscence)

Measure 226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

Quality Domain: Community / Population Health

Description: Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received cessation counseling intervention if identified as a tobacco user.

Numerator: Patients who were screened for tobacco use at least once within 24 months AND who received tobacco cessation intervention if identified as a tobacco user.

Definitions:

Tobacco Use – Includes use of any type of tobacco.

Tobacco Cessation Intervention – Includes brief counseling (3 minutes or less), and/or pharmacotherapy.

Numerator Options:

4004F Patient screened for tobacco use and received tobacco cessation counseling, if identified as a tobacco user

or

1036F Patient screened for tobacco use and identified as a non-user of tobacco

or

4004F 1P Tobacco screening not performed for medical reasons

or

4004F 8P Tobacco screening not performed reason not specified



Measure 303: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery

Quality Domain: Person and Caregiver-Centered Experience and Outcomes

Description: Percentage of patients aged 18 years and older in sample who had cataract surgery and had improvement in visual function achieved within 90 days following the cataract surgery, based on completing a pre-operative and postoperative visual function survey

Note:

- For patients who receive the cataract surgical procedures specified in the denominator coding in the sample, it should be reported whether or not the patient had improvement in visual function achieved within 90 days following the cataract surgery.
- Include only procedures performed through September 30 of the reporting period. This will allow the post-operative period to occur before registries must submit data to CMS.

Numerator Options:

G0913 Improvement in visual function achieved within 90 days following cataract surgery

or

G0914 Patient care survey was not completed by patient

or

G0915 Improvement in visual function **not** achieved within 90 days following cataract surgery

Measure 304: Patient Satisfaction within 90 Days Following Cataract Surgery

Quality Domain: Person and Caregiver-Centered Experience and Outcomes

Description: Percentage of patients aged 18 years and older in sample who had cataract surgery and were satisfied with their care within 90 days following the cataract surgery, based on completion of the Consumer Assessment of Healthcare Providers and Systems Surgical Care Survey

Note:

- For patients who receive the cataract surgical procedures specified in the denominator coding in the sample, it should be reported whether or not the patient was satisfied with their care within 90 days following the cataract surgery.
- Include only procedures performed through September 30 of the reporting period. This will allow the post-operative period to occur before registries must submit data to CMS.



Numerator Options:

G0916 Satisfaction with care achieved within 90 days following cataract surgery

or

G0917 Patient care survey was not completed by patient

or

G0918 Satisfaction with care **not** achieved within 90 days following cataract surgery

Measure 388: Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule requiring unplanned vitrectomy)

Quality Domain: Patient Safety

Description: Percentage of patients aged 18 years and older who had cataract surgery performed and had an unplanned rupture of the posterior capsule requiring vitrectomy.

Numerator: Patients who experienced an unplanned rupture of the posterior capsule requiring vitrectomy during cataract surgery.

Note:

- For patients who receive the surgical procedures specified in the denominator coding in the sample, it should be reported whether or not the patient had a rupture of the posterior capsule during anterior segment surgery requiring vitrectomy.
- Inverse measure: a lower calculated performance rate for this measure indicates better clinical care or control. The “Performance Not Met” numerator option for this measure is the representation of the better clinical quality or control. Reporting that numerator option will produce a performance rate that trends closer to 0%, as quality increases. For inverse measures a rate of 100% means all of the denominator eligible patients did not receive the appropriate care or were not in proper control, and therefore an inverse measure at 100% does not qualify for reporting purposes, however any reporting rate less than 100% does qualify.

Numerator Options:

G9389 Unplanned rupture of the posterior capsule requiring vitrectomy during cataract surgery.

or

G9390 No unplanned rupture of the posterior capsule requiring vitrectomy during cataract surgery.



Measure 389: Cataract Surgery: Difference Between Planned and Final Refraction

Quality Domain: Effective Clinical Care

Description: Percentage of patients who achieve planned refraction within ± 1.0 D of their planned (target) refraction.

Note:

- For patients who receive the surgical procedures specified in the denominator coding in the sample, it should be reported whether or not the patient had a difference between planned and final refraction.
- Include only procedures performed through September 30 of the reporting period. This will allow the post-operative period to occur before registries must submit data to CMS.

Numerator Options:

G9519 Patient achieves final refraction (spherical equivalent) ± 1.0 Diopters of their planned refraction within 90 days of surgery

or

G9520 Patient does not achieve final refraction (spherical equivalent) ± 1.0 Diopters of their planned refraction within 90 days of surgery
